Create a narrative

Supernus Pharmaceuticals Community

NasdaqGM:SUPN Community

1 Narratives written by author
0 Comments on narratives written by author
10 Fair Values set on narratives written by author

Supernus Pharmaceuticals

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 5 Analysts

Widening CNS Access Will Shape Long-term Market Opportunity

Key Takeaways Growth driven by expanding CNS patient pool, innovative product launches, and pipeline advancements supports higher revenue, margin expansion, and robust market positioning. Strong balance sheet and targeted acquisitions enable portfolio diversification, providing flexibility for inorganic growth and increased long-term shareholder value.

US$40.20

FV

6.2% overvalued

7.82%

Revenue growth p.a.

0

0

7

18 days ago